IL2 and renal cell carcinoma: In clinical practice, biological immunotherapy drugs such as interferon-α (IFN-α) and interleukin-2 (IL-2) are used for RCC, but their cytotoxicity is high, the adverse reactions are many, and the median survival time is not high [3–5].